ReviewJournal of Korean medical science2021
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
Review in Journal of Korean medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study.Virology journal · 2024Article
- Evaluation of patients of vaccine side effects after the COVID-19 vaccine.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.Human vaccines & immunotherapeutics · 2022Article
- Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines.Vaccines · 2022Article
- Antibodies to the Spike Protein Receptor-Binding Domain of SARS-CoV-2 at 4-13 Months after COVID-19.Journal of clinical medicine · 2022Article
- A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program.Future virology · 2022Review
- Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform.Osong public health and research perspectives · 2022Article
- Analyses of Confirmed COVID-19 Cases Among Korean Military Personnel After Mass Vaccination.Journal of Korean medical science · 2022Article
- Steroid injections in pain management: influence on coronavirus disease 2019 vaccines.The Korean journal of pain · 2022Review
- Durability of SARS-CoV-2 Specific IgG Antibody Responses Following Two Doses of Match and Mixed COVID-19 Vaccines Regimens in Saudi Population.Infection and drug resistance · 2022Article
- Advances in the design and development of SARS-CoV-2 vaccines.Military Medical Research · 2021Review
- DNA vaccines for SARS-CoV-2: toward third-generation vaccination era.Expert review of vaccines · 2021Review
- Analysis of a COVID-19 Prescreening Process in an Outpatient Clinic at a University Hospital during the COVID-19 Pandemic.Journal of Korean medical science · 2021Article
- Review
- Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea.Journal of Korean medical science · 2021Article
- China is facing serious experimental monkey shortage during the COVID-19 lockdown.Journal of medical primatology · 2021Review
- A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development.Pathogens (Basel, Switzerland) · 2021Review
- A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.RSC advances · 2021Review
- COVID-19: Insights into Potential Vaccines.Microorganisms · 2021Review
- An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and has spread worldwide, has remained unabated in 2021. Since non-pharmaceutical interventions including social distancing are facing limitations in controlling COVID-19, additional absolute means to change the trend are necessary. To this end, coronavirus-specific antiviral drugs and vaccines are urgently needed, but for now, the priority is to promote herd immunity through extensive nationwide vaccination campaign. In addition to the vaccines based on the conventional technology such inactivated or killed virus or protein subunit vaccines, several vaccines on the new technological platforms, for example, nucleic acids-based vaccines delivered by viral carriers, nanoparticles, or plasmids as a medium were introduced in this pandemic. In addition to achieving sufficient herd immunity with vaccination, the development of antiviral treatments that work specifically against COVID-19 will also be necessary to terminate the epidemic completely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.